Patents by Inventor Kaori Taniko
Kaori Taniko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9663463Abstract: The object of the present invention is to provide a compound having an antagonistic action against ?-opioid receptors, which causes less side effects and thus is highly safe. A compound represented by the general formula (I), or a pharmacologically acceptable salt thereof: wherein R1 and R2 are the same or different, and each represents a hydrogen atom or a halogen atom, provided that R1 and R2 are not simultaneously halogen atoms, R3 represents a C1-C3 alkyl group or a vinyl group, and R4 represents the formula (II): wherein R5 represents a hydroxy group or a C1-C3 alkoxy group, and R6 and R7 are the same or different, and each represents a hydrogen atom or a halogen atom; or the formula (III): wherein Ring A represents a halogen atom(s)-substituted C5-C7 cycloalkyl group which is optionally substituted by a C1-C3 alkoxy group, or a halogen atom(s)-substituted 5- to 7-membered saturated heterocyclic group.Type: GrantFiled: November 19, 2014Date of Patent: May 30, 2017Assignees: SANWA KAGAKU KENKYUSHO CO., LTD., UBE INDUSTRIES, LTD.Inventors: Kaori Taniko, Toshiyuki Miyazawa, Tatsuroh Kaneko, Daisuke Kurumazuka, Satoko Harada, Toru Izuchi, Morio Okabe, Ryo Iwamura, Yasunori Tsuzaki, Hiroyuki Setoguchi, Yuuki Imura, Hiroto Akaza, Motohisa Shimizu, Tomio Kimura
-
Publication number: 20160280645Abstract: The object of the present invention is to provide a compound having an antagonistic action against ?-opioid receptors, which causes less side effects and thus is highly safe. A compound represented by the general formula (I), or a pharmacologically acceptable salt thereof: wherein R1 and R2 are the same or different, and each represents a hydrogen atom or a halogen atom, provided that R1 and R2 are not simultaneously halogen atoms, R3 represents a C1-C3 alkyl group or a vinyl group, and R4 represents the formula (II): wherein R5 represents a hydroxy group or a C1-C3 alkoxy group, and R6 and R7 are the same or different, and each represents a hydrogen atom or a halogen atom; or the formula (III): wherein Ring A represents a halogen atom(s)-substituted C5-C7 cycloalkyl group which is optionally substituted by a C1-C3 alkoxy group, or a halogen atom(s)-substituted 5- to 7-membered saturated heterocyclic group.Type: ApplicationFiled: November 19, 2014Publication date: September 29, 2016Applicants: SANWA KAGAKU KENKYUSHO CO., LTD., UBE INDUSTRIES, LTD.Inventors: Kaori TANIKO, Toshiyuki MIYAZAWA, Tatsuroh KANEKO, Daisuke KURUMAZUKA, Satoko HARADA, Toru IZUCHI, Morio OKABE, Ryo IWAMURA, Yasunori TSUZAKI, Hiroyuki SETOGUCHI, Yuuki IMURA, Hiroto AKAZA, Motohisa SHIMIZU, Tomio KIMURA
-
Patent number: 8097640Abstract: A prophylactic or therapeutic agent for diabetic maculopathy, which can be administered for a long time and exhibits efficacy in a mechanism different from that of existing medicines. The invention relates to a prophylactic or therapeutic agent for diabetic maculopathy, comprising, as an active ingredient, a compound represented by the general formula: wherein X represents a halogen or a hydrogen atom, R1 and R2 concurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R1 and R2, together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle. Preferably, the compound is (2S,4S)-6-fluoro -2?,5?-dioxospiro chroman-4,4?-imidazolidine]-2-carboxamide. The invention also provides a model animal with diabetic maculopathy produced by subjecting a diabetic animal to intraocular ischemia/reperfusion to express edema in a retinal visual cell layer or in a macula lutea.Type: GrantFiled: July 23, 2010Date of Patent: January 17, 2012Assignee: Sanwa Kagaku Kenkyusho Co., Ltd.Inventors: Noriaki Kato, Hiroshi Nagano, Kaori Taniko, Takahito Jomori
-
Patent number: 7910615Abstract: A prophylactic or therapeutic agent for diabetic maculopathy, which can be administered for a long time and exhibits efficacy in a mechanism different from that of existing medicines. The invention relates to a prophylactic or therapeutic agent for diabetic maculopathy, comprising, as an active ingredient, a compound represented by the general formula: wherein X represents a halogen or a hydrogen atom, R1 and R2 concurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R1 and R2, together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle. Preferably, the compound is (2S,4S)-6-fluoro-2?,5?-dioxospiro[chroman-4,4?-imidazolidine]-2-carboxamide. The invention also provides a model animal with diabetic maculopathy produced by subjecting a diabetic animal to intraocular ischemia/reperfusion to express edema in a retinal visual cell layer or in a macula lutea.Type: GrantFiled: January 28, 2005Date of Patent: March 22, 2011Assignee: Sanwa Kagaku Kenkyusho Co., Ltd.Inventors: Noriaki Kato, Hiroshi Nagano, Kaori Taniko, Takahito Jomori
-
Publication number: 20100305177Abstract: A prophylactic or therapeutic agent for diabeticmaculopathy, which can be administered for a long time and exhibits efficacy in a mechanism different from that of existing medicines. The invention relates to a prophylactic or therapeutic agent for diabetic maculopathy, comprising, as an active ingredient, a compound represented by the general formula: wherein X represents a halogen or a hydrogen atom, R1 and R2 concurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R1 and R2, together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle. Preferably, the compound is (2S,4S)-6-fluoro-2?,5?-dioxospiro chroman-4,4?-imidazolidine]-2-carboxamide. The invention also provides a model animal with diabetic maculopathy produced by subjecting a diabetic animal to intraocular ischemia/reperfusion to express edema in a retinal visual cell layer or in a macula lutea.Type: ApplicationFiled: July 23, 2010Publication date: December 2, 2010Applicant: SANWA KAGAKU KENKYUSHO CO., LTD.Inventors: Noriaki KATO, Hiroshi Nagano, Kaori Taniko, Takahito Jomori
-
Publication number: 20070293556Abstract: A prophylactic or therapeutic agent for diabetic maculopathy, which can be administered for a long time and exhibits efficacy in a mechanism different from that of existing medicines. The invention relates to a prophylactic or therapeutic agent for diabetic maculopathy, comprising, as an active ingredient, a compound represented by the general formula: wherein X represents a halogen or a hydrogen atom, R1 and R2 concurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R1 and R2, together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle. Preferably, the compound is (2S, 4S)-6-fluoro-2?,5?-dioxospiro [chroman-4,4?-imidazolidine]-2-carboxamide.Type: ApplicationFiled: January 28, 2005Publication date: December 20, 2007Applicant: SANWA KAGAKUYUSHO CO., LTD.Inventors: Noriaki Kato, Hiroshi Nagano, Kaori Taniko, Takahiro Jomori